OBJECTIVE: To study the relationship between antiretroviral (ARV) treatment and abnormal ankle-branch index (ABI) and to compare the risk factors for altered ABI. METHODS: Patients coming to the office from April 2007 until July 2007 were offered the chance to take part in the study. ABI was obtained by the standard technique. Those < or = 0.9 or > or = 1.3 were considered altered ABI. Clinical reports were reviewed to examine traditional vascular risk factors, coinfection with hepatitis C virus and/or hepatitis B virus, tobacco use, highly active antiretroviral therapy use and its components and length of use of each ARV drug. RESULTS: ABI was measured in 147 patients, 82.3% males. Thirty-three patients (22.45%) had an altered ABI, and it was related to CD4 cell nadir, dyslipidaemia and protease inhibitor (PI) use. When logistic regression was carried out, only dyslipidaemia (OR 2.68, CI 95%: 1.06-6.91) and PI use (OR 2.79, CI 95%: 1.15-6.54) remained in the model. CONCLUSIONS: Altered ABI is associated with PI use independently of dyslipidaemia. Probably, it marks patients with high vascular risk not identified with traditional scales.
OBJECTIVE: To study the relationship between antiretroviral (ARV) treatment and abnormal ankle-branch index (ABI) and to compare the risk factors for altered ABI. METHODS:Patients coming to the office from April 2007 until July 2007 were offered the chance to take part in the study. ABI was obtained by the standard technique. Those < or = 0.9 or > or = 1.3 were considered altered ABI. Clinical reports were reviewed to examine traditional vascular risk factors, coinfection with hepatitis C virus and/or hepatitis B virus, tobacco use, highly active antiretroviral therapy use and its components and length of use of each ARV drug. RESULTS: ABI was measured in 147 patients, 82.3% males. Thirty-three patients (22.45%) had an altered ABI, and it was related to CD4 cell nadir, dyslipidaemia and protease inhibitor (PI) use. When logistic regression was carried out, only dyslipidaemia (OR 2.68, CI 95%: 1.06-6.91) and PI use (OR 2.79, CI 95%: 1.15-6.54) remained in the model. CONCLUSIONS: Altered ABI is associated with PI use independently of dyslipidaemia. Probably, it marks patients with high vascular risk not identified with traditional scales.
Authors: James J Jang; Aron I Schwarcz; Daniel A Amaez; Mark Woodward; Jeffrey W Olin; Marla J Keller; Alison D Schecter Journal: J Int AIDS Soc Date: 2010-03-22 Impact factor: 5.396
Authors: Emily Cedarbaum; Yifei Ma; Rebecca Scherzer; Jennifer C Price; Adaora A Adimora; Marcas Bamman; Mardge Cohen; Margaret A Fischl; Kunihiro Matsushita; Igho Ofotokun; Michael Plankey; Eric C Seaberg; Michael T Yin; Carl Grunfeld; Shant Vartanian; Anjali Sharma; Phyllis C Tien Journal: AIDS Date: 2019-11-01 Impact factor: 4.632
Authors: Julián Olalla; Elena Crespo; Javier De la Torre; Marco Sempere; Alfonso Del Arco; José Luis Prada; Rocío Malvarez; Javier Pérez; Javier García-Alegría Journal: AIDS Res Ther Date: 2015-05-10 Impact factor: 2.250
Authors: Wiesława Kwiatkowska; Brygida Knysz; Katarzyna Arczyńska; Justyna Drelichowska; Marcin Czarnecki; Jacek Gąsiorowski; Maciej Karczewski; Wojciech Witkiewicz Journal: PLoS One Date: 2014-12-12 Impact factor: 3.240
Authors: Félicité Kamdem; Yacouba Mapoure; Ba Hamadou; Fanny Souksouna; Marie Solange Doualla; Ahmadou Musa Jingi; Caroline Kenmegne; Fernando Kemta Lekpa; Jaff Kweban Fenkeu; Gisèle Imandy; Jean Pierre Nda Mefo'o; Henry Luma Journal: Vasc Health Risk Manag Date: 2018-12-06
Authors: Julián Olalla; Daniel Salas; Javier de la Torre; Alfonso Del Arco; José Luis Prada; Francisco Martos; Emilio Perea-Milla; Javier García-Alegría Journal: AIDS Res Ther Date: 2009-04-27 Impact factor: 2.250